Scarica l'app Stockscreener
6.72
1.66%
0.11
Dopo l'orario di chiusura:
6.82
0.10
+1.49%
Immuneering Corp Borsa (IMRX) Ultime notizie
Retail Trends: Will Immuneering Corporation stock see insider buyingCEO Change & Detailed Earnings Play Strategies - moha.gov.vn
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy - Yahoo Finance
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - Sahm
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP - TipRanks
Immuneering to provide 12-month survival data for pancreatic cancer drug - Investing.com
Immuneering to provide 12-month survival data for pancreatic cancer drug By Investing.com - Investing.com South Africa
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - The Manila Times
Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell - Defense World
Can Immuneering Corporation stock outperform in 2025 bull marketWeekly Trend Report & Long-Term Growth Plans - Улправда
Immuneering on track to dose first patient in pancreatic cancer trial in 2026 - MSN
Is Immuneering Corporation stock attractive for income investorsJuly 2025 Update & Stepwise Trade Signal Guides - Улправда
Why Immuneering Corporation stock attracts global investorsGlobal Markets & Accurate Buy Signal Notifications - Улправда
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026 - Nasdaq
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 - Investing.com Australia
Immuneering stock rises after FDA and EMA align on Phase 3 trial design By Investing.com - Investing.com South Africa
Immuneering stock rises after FDA and EMA align on Phase 3 trial design - Investing.com
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - The Manila Times
Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan
Immuneering to be added to the Nasdaq Biotechnology Index - TipRanks
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Immuneering (Nasdaq: IMRX) to be added to Nasdaq Biotechnology Index on Dec. 22 - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Sahm
Top investors say Immuneering Corp (IMRX) ticks everything they need - setenews.com
You Should Read This Analysis Before Investing in Immuneering Corp (NASDAQ:IMRX) - uspostnews.com
This trade activity should not be overlooked: Immuneering Corp (IMRX) - setenews.com
Immuneering (IMRX) Stock Analysis Report | Financials & Insights - Benzinga
We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth - Yahoo Finance
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Immuneering Corporation (IMRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A new trading data show Immuneering Corp (IMRX) is showing positive returns. - Setenews
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - simplywall.st
Combining machine learning predictions for Immuneering Corporation2025 Technical Overview & Technical Pattern Based Signals - newser.com
Best data tools to analyze Immuneering Corporation stockTrend Reversal & Stepwise Trade Execution Plans - newser.com
How Immuneering Corporation stock compares to growth peersLong Setup & Reliable Breakout Stock Forecasts - newser.com
Is Immuneering Corporation stock poised for growthBear Alert & Community Trade Idea Sharing - newser.com
Does Immuneering Corporation qualify in momentum factor screeningMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Can Immuneering Corporation stock reach $100 price targetEntry Point & Long-Term Safe Investment Plans - newser.com
Immuneering (IMRX) Gets a Buy from Mizuho Securities - The Globe and Mail
Will Immuneering Corporation stock beat EPS estimatesPortfolio Gains Report & High Win Rate Trade Alerts - newser.com
Can machine learning forecast Immuneering Corporation recoveryMarket Volume Report & Entry Point Confirmation Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Immuneering Corporation stock undervalued vs historical averages2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
What data driven models say about Immuneering Corporation’s futureMarket Activity Summary & Safe Entry Point Alerts - newser.com
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):